Skip to main content

Q/C Technologies, Inc.

QCLS
Exchange
Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
SEC CIK
0001321834

No open-market purchases or sales by Q/C Technologies, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $2.87M in total; no superinvestor holds it.

Q2 2025 vs. Q1 2025

How the institutions holding Q/C Technologies, Inc. changed between Q1 2025 and Q2 2025.

All holders in Q2 2025All holders in Q1 2025

13F holders of QCLS: Q1 2025 compared with Q2 2025
MeasureQ1 2025Of which not filed for Q2 2025Q2 2025Change
Holders24133+10
Shares197.3K116531.7K+334.5K (+169.6%)
Value$69.0K$41$65.3K−$3.68K (−5.3%)

1 institution that held it in Q1 2025 haven't filed for Q2 2025 yet. Not filing isn't selling, so the changes leave them out.

New holders (11)

Institutions that held Q/C Technologies, Inc. at the end of Q2 2025 but not at the end of Q1 2025.

Institutions new to QCLS in Q2 2025
InstitutionSharesValue% of portfolio
UBS Group AG64,984$7.99K0.00%
Two Sigma Securities, LLC50,603$6.21K0.00%
Goldman Sachs Group Inc45,451$5.58K0.00%
Jane Street Group, LLC35,241$4.33K0.00%
Cubist Systematic Strategies, LLC22,090$2.71K0.00%
StoneX Group Inc.11,989$1.47K0.00%
Raymond James Financial Inc368$450.00%
Atlantic Union Bankshares Corp116$150.00%
Allworth Financial LP67$90.00%
Legacy Investment Solutions, LLC60$80.00%
Ameritas Advisory Services, LLC17$20.00%

Sold out (1)

Institutions that held Q/C Technologies, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.

Institutions that sold out of QCLS in Q2 2025
InstitutionShares, Q1 2025Value, Q1 2025
Arvest Investments, Inc.34$11

Not filed for Q2 2025 yet (1)

Institutions that held Q/C Technologies, Inc. at the end of Q1 2025 and haven't filed a 13F for Q2 2025. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding QCLS in Q1 2025 that haven't filed for Q2 2025
InstitutionShares, Q1 2025Value, Q1 2025
Sandy Spring Bank116$41